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THE LEUCOCYTE adherence inhibition
J-JAI) test is an assay of cellular immune
reactivity capable ofmonitoring responses
in man and experimental animals to a
range of model antigens (Powell et al.,
1978). It has been widely used in the
investigation of immune recognition in
cancer patients, showing a high degree of
selectivity and sensitivity, and it was the
subject of a recent international workshop
(Cancer Re-seai-ch, 39, 551-662, 1-979). The
consensus of that meeting was that LAI
testing offered a promising adjunct to
currently availablediagnosticandmonitor-
ing procedures in cancer patients, having
the essential attributes of specificity and
correlation with clinical course. (Ilearly
there is a need forf-Lirtherstudy to evaltiate
the usefulness ofthis assay.
In this paper we report the results of a
series of tests carried out using the tech-
nique of Grosser & Thomson (1,975) on
blood samples taken from 44 women at
first presentation to the cliiiic with s-Lis-
pected breast disease. An essential feature
of this trial was that the diagnosis of the
disease was unknown at the time of test-
ing, being confirmed 1-3 weeks later by
clinical examination, mammography and
histology. A realistic assessment of the
immunodiagnostic value of LAI should
therefore be possible by comparison with
standardscreeningprocedures. Thesample
was supplemented with blood from 7
healthy hospital personnel, making a total
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of 51 women. Of the women presenting at
the clinic, 5 presented with breast pain
but showed no abnormality. Malignancy
was confirmed in 18 individuals, the
majority being infiltrating duct car-
cinoma, one of which was considered
advanced; histoloLyv revealed a medullary
carcinoma in one case, and a lobular car-
cinoma in another. Twenty-one patients
showed benign lesions, including 9 cysts,
6 fibroadenosis, 3 fibrocystic disease, I
lipoma, I calcification. and I duct ectasia.
The LAI assay was peorformed in tubes
using the method described by Grosser &
Thomson (1975) but with the following
differences: antigens were prepared from
2 breast carcinomas using a sample of
normal kidney as control, whereas Grosser
& Thomson used extracts of other car-
cinomas or normal breast tissue as con-
trols. We chose normal rather than malig-
nant tissue as the control in an attempt to
avoid possible cross-reactivities between
breast and other malignancies. The source
of control extracts, which take into ac-
count the nonspecific detachment of
leucocytes in the presence of extraneous
protein, has been shown to make little
difference to assay results (Lopez et al.,
1978). The antioens were titrated against
samples from bealthy donors and patients
with mammary carcinoma to determine
the concentration giving maximum dis-
crimination, i.e. giving minimal false-
positive reactions but with some reac-
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TABLE.-Typical LAI assays in human breast disease
No. non-adherent cellst in
presence of
r
Breast-tumour Normalkidney
antigen antigen
63,51,37 40,53,60
80,84,94 100,91,107
69,70,85 42,60,63
50,56,74 33,45,53
53,58,75 32,40,51
NAI*
-1-3
-13-4
35-8
37-3
35-4
Patient
V.E.
C.H.
M.W.
E.D.
D.W.
Diagnosis
No disease
Fibroadenosis
Cystic disease
Carcinoma
Carcinoma
No. cells non-adherent with No. non-adherent with kidney
breast-tumourantigen antigen
No. non-adherent with kidney antigen
* Non-adherent index= x 100
t No. cells in a standardhaemacytometer field.
tivity in the test group. All assays were
performed at that value (180 pg/ml final
concentration in the tubes). Grosser &
Thomson (1975) indicate that protein
concentrations of 100-440 /-tg/ml are
discriminatory, and later studies more
frequently use concentrations of -I00 jug/
ml (Lopez et al., 1978). Samples were
recoded before the counting of non-
adherent cellsby anindependentoperator.
Results are expressed as a non-adherence
index --"(NAI), which was calculated as
indicatq,d in Table 1. An arbitrary cut-off
of NAI = 25 was taken, since 95% of
healthy individuals tested gave NAI < 25.
Examples of the assay results are
presented in the Table and the data from
the entire series aredepicted in theFigure.
Positive reactivity (NAI >25) occurred
in 8/18 (44%) breast-cancer patients and
9/21 (43%) patients with benign lesions.
Only one healthy individual showed a
positive NAI. Among the patients with
breast disease no particular histology
showedhighreactivity and norelationship
was found to any known prognostic or
predisposing factor. In our hands the LAI
test has, therefore, failed to provide a
meaningful adjunct to the currently avail-
able diagnostic techniques, although dif-
ferent reactions were apparent between
individuals both with and without breast
disease.
Twomajorpointsdistinguish our results
from those of previous studies of LAI in
breast disease:
(1) A lower proportion (43%) of breast-
cancer patients have been shown to be
reactive than in several other studies, in
which the response rate was generally
above 60% (Grosser & Thomson, 1975;
Fritze el al., 1978; Lopez et al., 1978). This
could not be related to the stage ofdisease
since 17 of our 18 patients were Stage I
0
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(localized disease) or 11 (regional lymph
node metastases). It seems likely that
extracts may vary in their ability to
inhibit adherence, although a second ex-
tract used in parallel with the present
study showedentirely comparable activity
(data not shown). The use of pooled ex-
tracts may facilitate increased rates of
tumour detection (O'Connor et al., 1978).
(2) The high incidence of positive reac-
tions in unselected outpatients presenting
with benign disease has not previously
beenreported. Lopez et al. (I978) indicated
afalse-positive rate ofbetween 2 and .12%
depending on disease severity whilst
Sanner et al. (1979) found a mean response
rate of 24%, with some selectivity (up to
43% positive) for patients in high risk
groups. The reasons for our disparate
results remain unclear. The observation of
cross-reactivity betweenbenign andmalig-
nant diseases is, however, in accord with
several studies using migration inhibition
assays (LMI) in stomach (Z611er et al.,
-1.977), colon (Burtin et al., 1978) and
lung (Vose et al., 1977). Indeed cross-
reactivity in breast diseases has been
described in both cytotoxicity and LMI
assays (Avis et al., 1974; Cannon et al.,
1.978). The LAI assay has also failed to
distinguish benign from malignant liver
disorders (Dusheiko et al., 1979). Taken
together, these data suggest that liyper-
plasia or tissue breakdown associated
with disease mayinduceresponseto arange
of normal organ-related antigens in such
a way that the detection of tumour-
specific reactivity by assays of CMI may
be seriously compromised. If such a con-
c1usion is.correct, extracts of normaland
malignant breastfissue shouldgive similar
patterns of reactivity. This has not been
shown (Grosser & Thomson, 1975; Fritze
et al., 1978), although it is difficult to
obtain appropriate control material. Sen-
sitization to normal antigens would ac-
count for the frequently observed organ-
specific patterns ofreactivity in malignant
disease. The nature of the reactivity must
then remain unresolved. It is clear that
this assay has, in some laboratories,
considerable discriminatory powers. The
results of the present study suggest that
the test is not easily exploitable in the
routine examination of patients, a view
in accord'%i,ith that ofLopez etal., 1978.
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